GLP-1tirzepatidemounjarocardiovasculareli lilly

Medical Letter briefs clinicians on tirzepatide's new cardiovascular indication

The drug bulletin's October 12 in-brief covers the added Mounjaro indication for prescribers weighing incretin therapy beyond glycemic and weight endpoints.

By Maren Holt · Senior Reporter, GLP-1

Oct 5 19:00 ETSource: The Medical letter on drugs and therapeutics

The wire

01The Medical Letter on Drugs and Therapeutics published a short item on a cardiovascular indication for tirzepatide (Mounjaro) dated October 12, 2026.
02Independent drug bulletins shape prescribing habits, so a Medical Letter brief signals the indication is moving into routine clinical guidance.
03Only the brief's title is available here; clinicians should read the full item for the supporting trial data, population and any caveats.

From the source

In brief: A cardiovascular indication for tirzepatide (Mounjaro)
The Medical letter on drugs and therapeutics · 2026 Oct 12

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42832390/